Discussion of the updated WHO recommendations for mental, neurological, and substance use disorders
Lancet Psychiatry
.
2016 Nov;3(11):1008-1012.
doi: 10.1016/S2215-0366(16)30184-5.
Authors
Tarun Dua
1
,
Corrado Barbui
2
,
Archana A Patel
3
,
Elizabeth Centeno Tablante
4
,
Graham Thornicroft
5
,
Shekhar Saxena
4
;
WHO's mhGAP Guideline team
Affiliations
1
Department of Mental Health and Substance Abuse, World Health Organization, Geneva CH-1211, Switzerland. Electronic address: duat@who.int.
2
Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.
3
Department of Neurology, Division of Epilepsy and Clinical Neurophysiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
4
Department of Mental Health and Substance Abuse, World Health Organization, Geneva CH-1211, Switzerland.
5
Centre for Global Mental Health, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
PMID:
27794363
DOI:
10.1016/S2215-0366(16)30184-5
No abstract available
MeSH terms
Humans
Mental Disorders / therapy*
Nervous System Diseases / therapy*
Practice Guidelines as Topic*
Substance-Related Disorders / therapy*
World Health Organization*
Grants and funding
001/WHO_/World Health Organization/International